2026-02-24
Estrogen, Menopause, and Aging: Hormonal Mechanisms, Health Implications, and Protocol
Menopause-associated estrogen decline drives accelerated changes in cardiovascular risk, bone density, cognitive function, and metabolic health. Menopausal hormone therapy (MHT) has RCT and observational evidence supporting benefits for symptomatic relief and bone protection; cardiovascular and breast cancer risks depend on timing, type, and route of administration.
2026-02-24
GLP-1 Agonists and Aging: Metabolic Benefits, Cardiovascular Evidence, and Longevity Implications
GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular and metabolic benefits beyond weight reduction. This review covers the mechanistic basis, major trial evidence, and the open questions about their role in longevity medicine.
2026-02-24
Joint Health and Cartilage Support: What the Evidence Shows
Cartilage has limited self-repair capacity, but several interventions modestly slow degradation and reduce symptoms. Here is what the clinical evidence supports for joint health in aging.
2026-02-24
Kidney Health and Aging: GFR Decline, Protein Intake, and Renoprotective Strategies
GFR declines ~1 mL/min/year after age 40. In early-stage CKD, protein restriction, blood pressure control, and avoiding nephrotoxic supplements (high-dose oxalate, aristolochic acid) are the primary levers. Potassium citrate and omega-3 have supportive evidence.
2026-02-24
Longevity Biomarkers: What to Test, What the Results Mean, and How to Track Progress
Biological age testing spans conventional labs (HbA1c, CRP, lipids) to newer epigenetic clocks and proteomic aging scores. Most conventional biomarkers are actionable today; epigenetic clocks measure biological vs. chronological age but their clinical utility for intervention-guiding remains limited. A pragmatic panel of validated tests provides meaningful signal about longevity trajectory.